Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis

计划入组 3 人 · 首次发布于 2020 年 9 月 23 日

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

计划入组 698 人 · 首次发布于 2023 年 4 月 24 日

mRNA and miRNA Airway Inflammatory Markers

计划入组 21 人 · 首次发布于 2019 年 4 月 23 日

NTLA-2002

novel Cas9 mRNA gene-editing therapy (undisclosed indication)

KLKB1 mRNA encoded Cas9 gene therapy (hereditary angioedema)

Moderna, Inc.

United States

Intellia Therapeutics

United States

CRISPR Therapeutics

United States

Inhaled CRISPR-Cas9 Nanoparticles Target STING1 in Alveolar Macrophages to Reverse Pulmonary Fibrosis in Mice

Non-Viral CRISPR Therapy Shows Promise for Primary Hyperoxaluria Type 1 in Preclinical Study

Lipid Nanoparticles Enable Durable CRISPR Gene Editing in Muscle Stem Cells for Duchenne Muscular Dystrophy